These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18855625)

  • 1. GPR40 carboxylic acid receptor family and diabetes: a new drug target.
    Telvekar VN; Kundaikar HS
    Curr Drug Targets; 2008 Oct; 9(10):899-910. PubMed ID: 18855625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.
    Ghislain J; Poitout V
    Nat Rev Endocrinol; 2021 Mar; 17(3):162-175. PubMed ID: 33495605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G protein-coupled receptors as targets for anti-diabetic therapeutics.
    Oh DY; Olefsky JM
    Nat Rev Drug Discov; 2016 Mar; 15(3):161-72. PubMed ID: 26822831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty acid receptors as new therapeutic targets for diabetes.
    Rayasam GV; Tulasi VK; Davis JA; Bansal VS
    Expert Opin Ther Targets; 2007 May; 11(5):661-71. PubMed ID: 17465724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR40: a therapeutic target for mediating insulin secretion (review).
    Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
    Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40).
    Rodrigues DA; Pinheiro PSM; Ferreira TTDSC; Thota S; Fraga CAM
    Chem Biol Drug Des; 2018 Mar; 91(3):668-680. PubMed ID: 29068547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating GPR40: therapeutic promise and potential in diabetes.
    Poitout V; Lin DC
    Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.
    Talukdar S; Olefsky JM; Osborn O
    Trends Pharmacol Sci; 2011 Sep; 32(9):543-50. PubMed ID: 21663979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.
    Carullo G; Mazzotta S; Vega-Holm M; Iglesias-Guerra F; Vega-Pérez JM; Aiello F; Brizzi A
    J Med Chem; 2021 Apr; 64(8):4312-4332. PubMed ID: 33843223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids.
    Del Guerra S; Bugliani M; D'Aleo V; Del Prato S; Boggi U; Mosca F; Filipponi F; Lupi R
    Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):22-5. PubMed ID: 19758793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid binding receptors and their physiological role in type 2 diabetes.
    Swaminath G
    Arch Pharm (Weinheim); 2008 Dec; 341(12):753-61. PubMed ID: 19009545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.